drugset / Trial / NCT05423522
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
Timeline
- Start
- 2022-05-20
- Primary completion
- 2024-01-23
- Completion
- 2024-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NanoLithium® NP03 | Unknown | 1.8 mg | Other |
| Subject | NanoLithium® NP03 | Unknown | 3 ml | Other |